Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine
The Indianapolis-based drugmaker will partner with Profluent to develop and commercialize treatments for diseases with severe unmet needs.
Medical Research
-
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Read More -
IU medical school lands record $243M in NIH funding in 2023
The Indianapolis-based medical school ranked 29th in the country for landing funding from the National Institutes of Health.
Read More -
AI tools are helping researchers discover new drugs more quickly
During the last nine years, the cumulative amount of AI investments across the pharma and biotech sectors has increased by almost thirtyfold, to $24.6 billion as of last December.
Read More -
Lilly stock skyrockets, raising profile of city’s life sciences sector
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Read More
Articles
Q&A: Cardiologist has spent career working on treatment for rare condition
Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley Children’s Health, has been working on a treatment for a neurodegenerative condition called Friedreich’s ataxia for decades.
Ossium Health aims to revolutionize role of bone marrow banks
The company has a goal to build a massive bank of bone marrow from deceased organ donors to treat patients with blood cancers and improve organ transplantations.
Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies
Through the collaboration, Telix and Regeneron expect to develop and commercialize next-generation radiopharmaceutical therapies targeting cancer.
Indiana life sciences giant Philip Low dies at 78
Low founded seven companies based on intellectual property developed at Purdue, including Endocyte Inc., which he sold to Novartis Inc. in 2018 for $2.1 billion.
IU-Lilly study to explore drugs’ impact on job productivity
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
IU group among finalists for up to $160M to develop musculoskeletal health hub
The goal of the National Science Foundation’s Engines program is to grow regional innovation ecosystems.
State sells former GM stamping plant site to Elanco for $27M
Indiana Gov. Mike Braun said the agreement “enables Elanco and its partners, including Purdue University, to accelerate the creation of an innovation district in downtown Indianapolis.”
Supreme Court clears way for nearly $800M in cuts to NIH grants
Groups that filed the lawsuit to block the cuts said they represented “an unprecedented disruption to ongoing research” and threatened to undermine the NIH’s stature as a worldwide leader for diagnosing and treating illness.
Research on reversing Alzheimer’s reveals lithium as potential key
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
IU lands $16.5M grant to advance Alzheimer’s research using 3D brain modeling
The grant will fund a new center at the medical school which will be one of only two in the U.S. dedicated to developing stem-cell-based models of the brain to better understand Alzheimer’s disease.
RFK Jr. yanks $500M in funding for mRNA vaccine development
Health Secretary Robert F. Kennedy Jr. announced Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted.
Roche to test whether new drug can prevent Alzheimer’s
The new late-stage study will focus on people who are at risk of cognitive decline.
Drug manufacturing facility offers new hope in cancer fight
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
Trump administration appeals to Supreme Court to allow $783M in research funding cuts
The Justice Department argued that a federal judge was wrong to block the National Institutes of Health from making cuts to align with President Donald Trump’s priorities.
Komen Tissue Bank hosting breast tissue donation drive ahead of WNBA All-Star festivities
The event, a partnership between the tissue bank and the city’s WNBA All-Star 2025 Host Committee, seeks 500 women to donate breast tissue for cancer research.
IU professor’s work leads to Alzheimer’s blood test
Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.
Indianapolis-based startup leans on connections to treat brain diseases
Syndeio Biosciences sees burgeoning potential to treat mental health and cognitive conditions, including Alzheimer’s and depression, with therapies that target the almost countless minuscule brain synapses that give people the ability to think and function.
Lilly says weight loss pill has vast opportunity
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.